Nykode Therapeutics
Clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies.
Launch date
Employees
Market cap
AUD339m
Enterprise valuation
AUD74m (Public information from Sep 2024)
Share price
NOK5.05 NYKD.OL
Company register number 990646066
Oslo Norway (HQ)
Financials
Estimates*
NOK | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 1.8b | 281m | 59.2m | 107m | 104m | 249m | 107m |
% growth | 3204304 % | (84 %) | (79 %) | 80 % | (2 %) | 139 % | (57 %) |
EBITDA | 1.5b | (85.7m) | (405m) | (345m) | (609m) | (613m) | (1.0b) |
% EBITDA margin | 84 % | (31 %) | (684 %) | (324 %) | (584 %) | (246 %) | (976 %) |
Profit | 1.2b | (77.8m) | (353m) | (290m) | (540m) | (678m) | (942m) |
% profit margin | 70 % | (28 %) | (596 %) | (272 %) | (517 %) | (273 %) | (880 %) |
EV / revenue | 12.0x | 76.6x | 104.1x | 50.0x | 7.9x | 6.5x | 25.4x |
EV / EBITDA | 14.3x | -250.8x | -15.2x | -15.4x | -1.4x | -2.6x | -2.6x |
R&D budget | 87.8m | 135m | 221m | 243m | - | - | - |
R&D % of revenue | 5 % | 48 % | 374 % | 228 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Grant | ||
$2.6m | Grant | ||
* | NOK2.5m | Seed | |
$6.9m | Late VC | ||
$25.0m Valuation: $44.9m | Late VC | ||
NOK4.0m | Grant | ||
N/A | N/A | IPO | |
* | N/A | $45.0m | Private Placement VC |
Total Funding | AUD124m |
Related Content
Recent News about Nykode Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.